Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2025 09:00 ET | Source: Accendatech

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

A new approach is needed to address huge unmet medical needs in tissue denegerative disease such as IPF. Several efforts were discussed in this article.